Results 171 to 180 of about 110,178 (262)

BCOR Mutations Deregulate Cell Cycle and Hypoxic Adaptation Pathways in Retinoblastoma. [PDF]

Mol Cancer Res
Zhang MG, Kuznetsoff JN, Cetta NC, Salazar S, Volonterio RL, Kurtenbach S, Correa ZM, Pelaez D, Harbour JW.   +8 more
europepmc   +1 more source

CSPG4 Mediates Inflammatory, Cell Death, and Senescence Responses in Enteric Glia Exposed to Clostridioides difficile Toxins

The FASEB Journal, Volume 40, Issue 8, 30 April 2026.
Enteric glia in humans, mice, and rats express all known receptors for TcdA (LDLR) and TcdB (CSPG4, FZD‐1, FZD2, FZD7, PVRL3, TFPI, LRP1). CSPG4 expression is increased in colonic tissues from humans and mice with C. difficile infection, as well as in rat enteric glia exposed to TcdA or TcdB. C.
Francisco M. S. Marques, Deiziane V. S. Costa, Conceição S. M. Rebouças, Gerly A. C. Brito, Cirle A. Warren, Renata F. C. Leitão   +5 more
wiley   +1 more source

Recurrent Bronchospasm During Intra-arterial Chemotherapy via IMAX Access for Retinoblastoma: A Case Report. [PDF]

Cureus
Huang R, Muthu P, Najera M.
europepmc   +1 more source

THE MANAGEMENT OF RETINOBLASTOMA [PDF]

Australian and New Zealand Journal of Ophthalmology, 1980
openaire   +2 more sources

p21 Knockdown as a Therapeutic Strategy for Focal Cartilage Injury Repair

The FASEB Journal, Volume 40, Issue 8, 30 April 2026.
Intraarticular injection of lentiviral p21 shRNA (targeting Cdkn1a) into murine knees with full‐thickness cartilage defects reduces chondrocyte senescence while enhancing matrix repair with minimal hepatic off‐target effects. ABSTRACT Focal articular cartilage defects lack intrinsic regenerative capacity and can progress to osteoarthritis as no ...
Leila Larijani, Aria Ahadzadeh Ardebili, Nini Ortiz Vales, Andreas T. Stürmer, Roman J. Krawetz   +4 more
wiley   +1 more source

Revisiting low penetrance retinoblastoma: an integrated clinical, genetic, and bioinformatic analysis. [PDF]

Hum Mol Genet
Avnat E, Shapira G, Lustig Y, Citrin J, Rojanaporn D, Kaewkhaw R, Jo DH, Kim JH, Shomron N, Friedman E, Fabian ID.   +10 more
europepmc   +1 more source

B7-H3 and GD2 overexpression as immunotherapeutic targets in retinoblastoma. [PDF]

Sci Rep
Sujjitjoon J, Ng WL, Kongkla K, Jarutatsanangkoon K, Chongsutakawewong K, Subhadhirasakul S, Uiprasertkul M, Udompunturak S, Junking M, Yenchitsomanus PT, Atchaneeyasakul LO.   +10 more
europepmc   +1 more source

Retinoblastoma in times of war: changing patterns of presentation, treatment, and prognosis in Gaza. [PDF]

Front Oncol
Yousef YA, Msallam M, Mohammad M, Halalsheh H, Khzouz J, Al-Hussaini M, Jaradat I, Shawagfeh M, Sultan I, Mehyar M, Al-Nawaiseh I, Mansour A.   +11 more
europepmc   +1 more source

High-throughput screening of drug libraries identifies a new synergistic drug combination for the treatment of retinoblastoma. [PDF]

PLoS One
Tseng PJ, Sinenko IL, Chambon M, Banfi D, Zugbi S, Cancela MB, Glinkina KA, Turcatti G, Stathopoulos C, Schaiquevich P, Munier FL, Dyson PJ.   +11 more
europepmc   +1 more source

Targeting MCM6 Enhances Melphalan Chemosensitivity in Retinoblastoma by Modulating DNA Damage Response. [PDF]

Invest Ophthalmol Vis Sci
Wang M, Tang J, Li J, Lv J, Zhang Z, Liu Y, Sun H, Gao Y, Chen S, Tang L, Zhang P, Su S, Lu R.   +12 more
europepmc   +1 more source